http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 18:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+ROBIN+HOWARD+W/26814510.html si-local-file:///var/storage/secattach/20260724/26814510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+ROBIN+HOWARD+W/26814510.html Fri, 24 Jul 2026 18:35:00 -0400 NKTR O.00168666 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+ROBIN+HOWARD+W/26814510.html si-local-file:///var/storage/secattach/20260724/26814510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+ROBIN+HOWARD+W/26814510.html Fri, 24 Jul 2026 18:35:00 -0400 NKTR O.00168666 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+Zalevsky+Jonathan/26814511.html si-local-file:///var/storage/secattach/20260724/26814511.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+Zalevsky+Jonathan/26814511.html Fri, 24 Jul 2026 18:35:00 -0400 NKTR O.00168666 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+Zalevsky+Jonathan/26814511.html si-local-file:///var/storage/secattach/20260724/26814511.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEKTAR+THERAPEUTICS+++++++For%3A+Jul+24++Filed+by%3A+Zalevsky+Jonathan/26814511.html Fri, 24 Jul 2026 18:35:00 -0400 NKTR O.00168666 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location></span>, <span class="legendSpanClass"><chron>July 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NKTR" idsrc="xmltag.org" >Nektar Therapeutics</span> (NASDAQ: NKTR) today announced that, on <chron>July 20, 2026</chron>, the Organization and <span>Compensation Committee</span> of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html Fri, 24 Jul 2026 16:15:00 -0400 NKTR O.00168666 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location></span>, <span class="legendSpanClass"><chron>July 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NKTR" idsrc="xmltag.org" >Nektar Therapeutics</span> (NASDAQ: NKTR) today announced that, on <chron>July 20, 2026</chron>, the Organization and <span>Compensation Committee</span> of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html Fri, 24 Jul 2026 16:15:00 -0400 NKTR O.00168666 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location></span>, <span class="legendSpanClass"><chron>July 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NKTR" idsrc="xmltag.org" >Nektar Therapeutics</span> (NASDAQ: NKTR) today announced that, on <chron>July 20, 2026</chron>, the Organization and <span>Compensation Committee</span> of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html Fri, 24 Jul 2026 16:15:00 -0400 NKTR O.00168666 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location></span>, <span class="legendSpanClass"><chron>July 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NKTR" idsrc="xmltag.org" >Nektar Therapeutics</span> (NASDAQ: NKTR) today announced that, on <chron>July 20, 2026</chron>, the Organization and <span>Compensation Committee</span> of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26813676.html Fri, 24 Jul 2026 16:15:00 -0400 NKTR O.00168666 http://www.streetinsider.com/New+Coverage/Canaccord+Starts+Nektar+Therapeutics+%28NKTR%29+at+Buy/26797355.html <p>Canaccord analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $153.00.</p> <p>For an analyst ratings summary and ratings history on Nektar Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=NKTR">click here</a>. For more ratings news on Nektar Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=NKTR&amp;type=analyst">click here</a>.</p> <p>Shares of Nektar Therapeutics closed at $68.67 yesterday.</p> http://www.streetinsider.com/New+Coverage/Canaccord+Starts+Nektar+Therapeutics+%28NKTR%29+at+Buy/26797355.html Wed, 22 Jul 2026 05:52:34 -0400 NKTR http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html <p>Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis.</p> <p>The ZENITH AD program consists of three randomized, double-blind, placebo-controlled trials targeting a total enrollment of 1,530 patients across North America, Europe, and Asia-Pacific. ZENITH AD-1 and ZENITH AD-2 will enroll patients who are biologic and systemic JAK inhibitor treatment-naive, while a third study, ZENITH AD-3, targeting treatment-experienced patients, is set to begin in September.</p> <p>Each trial includes a 24-week induction period in which patients receive rezpegaldesleukin or placebo every two http://www.streetinsider.com/FDA/Nektar+starts+Phase+3+trials+for+eczema+drug+rezpegaldesleukin/26791995.html Tue, 21 Jul 2026 07:00:39 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/Press+Releases/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661 http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html <div class="xn-content"> <p class="prntac"><i>Two global registrational Phase 3 trials initiated in ZENITH AD program</i></p><p class="prntac"><i>Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed </i><i>in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in <span value="ACORN:3674758610" idsrc="xmltag.org" >EASI</span>-100 between 16 and 52 weeks</i></p><p class="prntac"><i>ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September</i></p><p class="prntac"><i>Initial Phase 3 topline data expected in mid-2028 with BLA http://www.streetinsider.com/PRNewswire/Nektar+Therapeutics+Announces+Start+of+Phase+3+ZENITH+AD+Program+Evaluating+Novel+Regulatory+T-Cell+Biologic+Rezpegaldesleukin+in+Moderate-to-Severe+Atopic+Dermatitis/26791988.html Tue, 21 Jul 2026 07:00:00 -0400 A.31066700 A.36747586 NKTR O.00036564 O.00168666 O.22422661